PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
Kim Linton,
Francesco Forconi,
David Lewis,
John Riches,
Dima El-Sharkawi,
Mary Gleeson,
Sarah G Injac,
Srinand Nandakumar,
May Tan,
Ganesh Cherala,
Graham P Collins
Affiliations
Kim Linton
1 Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, United Kingdom
Francesco Forconi
2 University Hospital Southampton NHS Trust, Southampton, United Kingdom
David Lewis
3 Derriford Hospital, Plymouth, United Kingdom
John Riches
4 Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Dima El-Sharkawi
5 Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Mary Gleeson
6 Sarah Cannon Research Institute, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
Sarah G Injac
7 Nurix Therapeutics, Inc., San Francisco, United States
Srinand Nandakumar
8 Nurix Therapeutics, Inc., San Francisco, United States
May Tan
7 Nurix Therapeutics, Inc., San Francisco, United States
Ganesh Cherala
7 Nurix Therapeutics, Inc., San Francisco, United States
Graham P Collins
9 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
